The use of sphingolipids and, synthetic sphingolipid analogs, or newly developed SET inhibitors, as cancer therapeutics is likely to increase as we are better able to target SET to reactivate PP2A, leading to tumor suppression. This evidence concerns the gene PTPA and neoplasm.